Últimas noticias sobre Eli Lilly (NYSE:LLY) Bolsa

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Equities

News

Markets

Tech

General

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TEVA

TSLA

Stanley Druckenmiller vendió todas sus acciones en Broadcom tras su alza del 100% y reforzó su inversión en grandes tecnológicas.

El nuevo giro de Druckenmiller: vende Broadcom y amplía su apuesta en tecnológicas clave

Analyst Color

Earnings

Futures

Economics

Pre-Market Outlook

Analyst Ratings

FTNT

RANI

RBLX

SANG

Las acciones de EE.UU. suben mientras los inversores analizan los aranceles, resultados financieros y expectativas de la Fed.

Los futuros de Wall Street suben: ¿Cómo impactarán los aranceles y las ganancias empresariales?

Short Sellers

Price Target

Trading Ideas

Eli Lilly proyecta ingresos récord y los analistas ajustan sus precios objetivo. ¿Cómo afectará esto a sus acciones? Descúbrelo aquí.

Análisis de Eli Lilly (LLY): los expertos ajustan precios objetivo tras su impresionante crecimiento

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

On Monday, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44069717/abbvie-and-gubra-announce-license-agreement-to-develop-an-amylin-analog-for-the-treatment-of-obesi" rel="noreferrer noopener">Phase 1 clinical trial</a>.
&#8220;Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company,&#8221; said&nbsp;Robert Michael, CEO of AbbVie.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts" rel="noreferrer noopener">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a>
A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors.
Amylin, a satiety hormone, has been identified as a potential therapeutic target for obesity, given its role in activating signals to the brain that result in appetite suppression and the reduction of food intake while also acting as an inhibitory signal to delay gastric emptying.&nbsp;
Under the terms of the agreement, AbbVie will lead the development and commercialization activities of GUB014295 globally.
Gubra will receive&nbsp;$350 million&nbsp;in total upfront payment and be eligible to receive up to&nbsp;$1.875 billion&nbsp;in development, commercial and sales milestone payments with tiered royalties on global net sales.
William Blair analyst Matt Phipps writes, &#8220;We believe this transaction highlights a growing interest in amylin agonists (and particularly dual amylin/calcitonin receptor agonists, or DACRAs) as a next wave of obesity assets, particularly for companies looking to break into the field despite being well behind GLP-1 leaders Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).&#8221;
The analyst highlights a key question is whether AbbVie will develop GUB014295 as a standalone treatment, offering a milder weight loss option for those who cannot tolerate or do not respond to GLP-1/GIP agonists.
Alternatively, the company may combine it with GLP-1/GIP drugs like Novo Nordisk's CagriSema for greater weight loss. Investors are also interested in whether AbbVie plans to expand further in the obesity market through new business deals.
Price Action: ABBV stock is up 0.84% at $210.78 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44080418/trimble-and-stmicroelectronics-launch-precision-positioning-tech-for-iot-applications" target="_blank" rel="noreferrer noopener">Trimble, STMicroelectronics Launch Precision Positioning Tech For IoT Applications</a></li>
</ul>
Photo via Shutterstock.

Biotech

Large Cap

Health Care

ABBV

GUBRF

AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly.
Looking at options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) we detected 33 trades.
If we consider the specifics of each trade, it is accurate to state that 51% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $425,075 and 22, calls, for a total amount of $2,632,262.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $380.0 to $1050.0 for Eli Lilly during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Eli Lilly stands at 500.96, with a total volume reaching 3,543.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $380.0 to $1050.0, throughout the last 30 days.
<h3>Eli Lilly 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741017692_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$129.9</td>
<td>$127.7</td>
<td>$129.8</td>
<td>$860.00</td>
<td>$1.7M</td>
<td>1.2K</td>
<td align="right">134</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$155.75</td>
<td>$146.55</td>
<td>$155.75</td>
<td>$1000.00</td>
<td>$155.7K</td>
<td>118</td>
<td align="right">1</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$190.2</td>
<td>$189.0</td>
<td>$189.0</td>
<td>$740.00</td>
<td>$75.6K</td>
<td>158</td>
<td align="right">4</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.75</td>
<td>$8.3</td>
<td>$8.3</td>
<td>$880.00</td>
<td>$67.2K</td>
<td>1.2K</td>
<td align="right">114</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$544.65</td>
<td>$537.85</td>
<td>$541.78</td>
<td>$380.00</td>
<td>$54.1K</td>
<td>10</td>
<td align="right">2</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>With a trading volume of 735,787, the price of LLY is up by 0.32%, reaching $923.6.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 59 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $1038.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1038. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Eli Lilly's Options Frenzy: What You Need to Know

Editor&#8217;s Note: The story has been updated to correct the new site locations
At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical <a href="https://www.benzinga.com/pressreleases/25/02/n43973825/lilly-plans-to-more-than-double-u-s-manufacturing-investment-since-2020-exceeding-50-billion" target="_blank" rel="noreferrer noopener">manufacturing sites in the United States</a>. The company is currently negotiating with several states. The company&#8217;s previous total domestic capital expansion commitments from 2020 to <a href="https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-facility" target="_blank" rel="noreferrer noopener">2024 totaled $23 billion</a>.
This brings the company&#8217;s total U.S. capital expansion commitments to over&nbsp;$50 billion&nbsp;since 2020.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43938612/eli-lilly-expands-zepbound-vial-options-lowers-prices-for-25-mg-5-mg-doses" rel="noreferrer noopener">Eli Lilly Expands Zepbound Vial Options, Lowers Prices For 2.5 mg, 5 Mg Doses</a>
Eli Lilly expects to announce all four future site locations in 2025 and anticipates facilities will begin making medicines for patients within five years.
<ul>
<li>Three of the future U.S. sites announced will focus on manufacturing active pharmaceutical ingredients (APIs), reshoring critical capabilities of small-molecule chemical synthesis, and further strengthening Lilly&#8217;s supply chain.</li>
<li>The fourth location will extend the company&#8217;s global parenteral manufacturing network for future injectable therapies.</li>
</ul>
Lilly expects to create more than 3,000 jobs for highly skilled workers at these four new sites, including engineers, scientists, operations personnel, and lab technicians. Additionally, the company anticipates that it could create nearly 10,000 construction jobs during the development of the sites.
&#8220;The Tax Cuts and Jobs Act legislation passed in 2017 during President Trump&#8217;s first term in office has been foundational to Lilly&#8217;s domestic manufacturing investments, and it is essential that these policies are extended this year,&#8221; said&nbsp;David Ricks, Lilly chair and CEO.
In May 2024, Eli Lilly&nbsp;more than doubled its investment in its&nbsp;Lebanon, Indiana, manufacturing site with a new&nbsp;$5.3 billion&nbsp;commitment, increasing its total investment&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39012514/eli-lilly-makes-largest-manufacturing-investment-in-its-history-to-boost-production-for-antidiabe" rel="noreferrer noopener">from&nbsp;$3.7 billion to&nbsp;$9 billion</a>.&nbsp;
In October, Eli Lilly announced a&nbsp;$4.5 billion&nbsp;investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41141028/eli-lilly-invests-4-5b-in-new-medicine-foundry-for-advanced-drug-manufacturing-to-push-us-pharma-" rel="noreferrer noopener">and drug development</a>.
Price Action: LLY stock is down 0.42% at $901.40 premarket at the last check on Friday. (updated)
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43973849/budweiser-parent-anheuser-busch-says-beer-is-a-passion-point-for-consumers-on-strong-q4-performance" target="_blank" rel="noreferrer noopener">Budweiser Parent Anheuser-Busch Says &#8216;Beer Is A Passion Point For Consumers&#8217; On Strong Q4 Performance</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target (CORRECTED)

The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting&nbsp;
BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor
INDIANAPOLIS, Feb. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor,&nbsp;for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have been previously treated with a BTK inhibitor.

Lilly's Jaypirca Recommended By CHMP For Approval In The EU For Adults With Relapsed Or Refractory Chronic Lymphocytic Leukemia Previously Treated With A BTK Inhibitor

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$42.00</td>
<td>$33.4K</td>
<td>6.5K</td>
<td>5.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$27.00</td>
<td>$47.3K</td>
<td>322</td>
<td>2.3K</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$65.00</td>
<td>$28.0K</td>
<td>11.9K</td>
<td>672</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$87.00</td>
<td>$30.2K</td>
<td>6</td>
<td>500</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$43.00</td>
<td>$41.2K</td>
<td>5.7K</td>
<td>81</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$56.9K</td>
<td>1.9K</td>
<td>80</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$915.00</td>
<td>$32.2K</td>
<td>177</td>
<td>66</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$30.00</td>
<td>$34.0K</td>
<td>6.0K</td>
<td>50</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$520.00</td>
<td>$58.0K</td>
<td>962</td>
<td>40</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$310.00</td>
<td>$53.0K</td>
<td>38</td>
<td>19</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option trade that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $42.00 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $334.0 per contract. There were 6534 open contracts at this strike prior to today, and today 5139 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bearish sentiment. It expires in 29 day(s) on March 28, 2025. Parties traded 720 contract(s) at a $27.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $47.3K, with a price of $65.0 per contract. There were 322 open contracts at this strike prior to today, and today 2378 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option sweep that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $65.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 11949 open contracts at this strike prior to today, and today 672 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a put option trade that happens to be bearish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 144 contract(s) at a $87.00 strike. The total cost received by the writing party (or parties) was $30.2K, with a price of $210.0 per contract. There were 6 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a call option trade that happens to be bullish, expiring in 323 day(s) on January 16, 2026. This event was a transfer of 25 contract(s) at a $43.00 strike. The total cost received by the writing party (or parties) was $41.2K, with a price of $1650.0 per contract. There were 5751 open contracts at this strike prior to today, and today 81 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 323 day(s) on January 16, 2026. Parties traded 67 contract(s) at a $230.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $56.9K, with a price of $850.0 per contract. There were 1944 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with neutral sentiment. It expires in 8 day(s) on March 7, 2025. Parties traded 15 contract(s) at a $915.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $2150.0 per contract. There were 177 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
• Regarding BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we observe a call option trade with bullish sentiment. It expires in 78 day(s) on May 16, 2025. Parties traded 50 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $680.0 per contract. There were 6077 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bearish sentiment. It expires in 113 day(s) on June 20, 2025. Parties traded 10 contract(s) at a $520.00 strike. The total cost received by the writing party (or parties) was $58.0K, with a price of $5800.0 per contract. There were 962 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 204 day(s) on September 19, 2025. This event was a transfer of 19 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $53.0K, with a price of $2790.0 per contract. There were 38 open contracts at this strike prior to today, and today 19 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBIO

DXCM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

SWTX

10 Health Care Stocks Whale Activity In Today's Session

Last week, the Food and Drug Administration (FDA) said Novo Nordisk A/' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide products, including Wegovy and Ozempic, are no longer in shortage.
Semaglutide injection products were <a target="_blank" href="https://www.fda.gov/media/185526/download?attachment" rel="noreferrer noopener">first</a> added to the FDA's drug shortage list for Wegovy in March 2022 and Ozempic in August 2022.
A lawsuit filed by the compounding groups Outsourcing Facilities Association (OFA) and North American Custom Laboratories, doing business as FarmaKeio Superior Custom Compounding, challenges the FDA's decision to remove semaglutide from the drug shortage list.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43812904/novo-nordisk-sues-singapore-based-kbp-biosciences-over-alleged-data-misrepresentation-in-13-billion-hypertension-drug-deal-seeks-over-800-million-in-damages" rel="noreferrer noopener">Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages</a>
The plaintiffs argue that this action was arbitrary, unlawful, and detrimental to patients who rely on compounded semaglutide for type 2 diabetes, obesity, and cardiovascular disease.
The <a target="_blank" href="https://www.503bs.org/_files/ugd/90544a_2f297f7c5f2a45fb89f64fe6a5dcb5c7.pdf" rel="noreferrer noopener">lawsuit</a> highlights that even the manufacturer of FDA-approved semaglutide acknowledged in its earnings release that supply issues and drug <a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" rel="noreferrer noopener">shortages were ongoing</a>.
Despite this, the FDA proceeded with its decision without engaging in a formal notice-and-comment rulemaking process, which plaintiffs argue violates the Administrative Procedure Act (APA).
The APA requires federal agencies to provide public notice, solicit input from stakeholders, and offer reasoned explanations for regulatory actions.
In December, Novo Nordisk&nbsp;submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of substances that outsourcing facilities may <a target="_blank" href="https://www.benzinga.com/25/01/42811734/novo-nordisk-pushes-fda-to-exclude-compounding-for-its-early-generation-diabetes-drug" rel="noreferrer noopener">use in drug compounding</a>.
The petition argues that FDA-approved liraglutide-based products, Victoza, Saxenda, and Xultophy, meet patient needs without requiring additional compounded versions, which Novo Nordisk contends pose significant safety and efficacy risks.
Last year, the FDA determined that the Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide injection shortage had been resolved.
The compounding groups <a target="_blank" href="https://www.503bs.org/_files/ugd/90544a_956a40069f7c4b768199e187953cd15f.pdf" rel="noreferrer noopener">filed</a> a complaint alleging that removing the drug from the shortage list is based solely on the manufacturer's production capabilities.
In January, Eli Lilly filed a motion to intervene as a defendant in a case against the FDA brought by the Outsourcing Facilities Association and <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42783449/eli-lilly-joins-fda-lawsuit-over-compounded-obesity-drugs-seeks-swift-end-and-to-protect-its-interests" rel="noreferrer noopener">FarmaKeio Custom Compounding</a>.
Price Action: LLY stock is up 1.22% at $912.79 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43980584/united-parks-q4-earnings-miss-estimates-as-unusually-poor-weather-impacts-results" target="_blank" rel="noreferrer noopener">United Parks Q4 Earnings Miss Estimates As ‘Unusually Poor' Weather Impacts Results</a></li>
</ul>
Image via Shutterstock

Legal

Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$48.00</td>
<td>$81.9K</td>
<td>541</td>
<td align="right">474</td>
</tr>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$380.00</td>
<td>$74.5K</td>
<td>42</td>
<td align="right">88</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$295.00</td>
<td>$34.6K</td>
<td>148</td>
<td align="right">31</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$26.3K</td>
<td>2.6K</td>
<td align="right">26</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$110.00</td>
<td>$25.4K</td>
<td>86</td>
<td align="right">25</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$300.00</td>
<td>$91.7K</td>
<td>3</td>
<td align="right">15</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$960.00</td>
<td>$120.4K</td>
<td>79</td>
<td align="right">10</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$480.00</td>
<td>$27.2K</td>
<td>1.1K</td>
<td align="right">9</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$280.00</td>
<td>$32.2K</td>
<td>2</td>
<td align="right">6</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$590.00</td>
<td>$26.2K</td>
<td>7</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with neutral sentiment. It expires in 50 day(s) on April 17, 2025. Parties traded 200 contract(s) at a $48.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $81.9K, with a price of $410.0 per contract. There were 541 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• For MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we notice a call option sweep that happens to be bearish, expiring in 50 day(s) on April 17, 2025. This event was a transfer of 25 contract(s) at a $380.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $74.5K, with a price of $2970.0 per contract. There were 42 open contracts at this strike prior to today, and today 88 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be neutral, expiring in 2 day(s) on February 28, 2025. This event was a transfer of 25 contract(s) at a $295.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $1387.0 per contract. There were 148 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be neutral, expiring in 324 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $1315.0 per contract. There were 2612 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with neutral sentiment. It expires in 79 day(s) on May 16, 2025. Parties traded 25 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $1020.0 per contract. There were 86 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with neutral sentiment. It expires in 2 day(s) on February 28, 2025. Parties traded 5 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $91.7K, with a price of $18346.0 per contract. There were 3 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bearish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $960.00 strike. The total cost received by the writing party (or parties) was $120.4K, with a price of $12040.0 per contract. There were 79 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 5 contract(s) at a $480.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $5455.0 per contract. There were 1141 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bearish sentiment. It expires in 387 day(s) on March 20, 2026. Parties traded 6 contract(s) at a $280.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $5383.0 per contract. There were 2 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bullish, expiring in 688 day(s) on January 15, 2027. This event was a transfer of 5 contract(s) at a $590.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $5258.0 per contract. There were 7 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMGN

MDGL

SRPT

TGTX

VRTX

Lilly Expects To Begin Building Four More Domestic Manufacturing Sites This Year

Organovo Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares are trading higher by 198.1% to $1.12 Tuesday morning after the company announced that Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is set to acquire its <a href="https://www.benzinga.com/pressreleases/25/02/g43938381/organovos-fxr-program-including-fxr314-to-be-acquired-by-eli-lilly-and-company">FXR program</a>, including FXR314.
What To Know: San Diego-based biotechnology company Organovo announced that Eli Lilly will acquire its FXR program, including lead asset FXR314, aimed at treating inflammatory bowel disease. Organovo Executive Chairman Keith Murphy called the deal a major milestone, highlighting Lilly's expertise in drug development.
The agreement includes an upfront payment to Organovo, along with potential milestone payments tied to regulatory and commercial achievements. Lilly will gain full commercial and intellectual property rights to the FXR program for global development. 
Read Also: <a href="https://www.benzinga.com/news/earnings/25/02/43937535/home-depot-lifts-annual-dividend-after-strong-q4-but-soft-2025-outlook-weighs-on-stock">Home Depot Lifts Annual Dividend After Strong Q4, But Soft 2025 Outlook Weighs On Stock</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ONVO has a 52-week high of $1.74 and a 52-week low of $0.32.

ONVO

Why Organovo (ONVO) Stock Is Skyrocketing

On Tuesday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) launched 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for&nbsp;$499&nbsp;with the new Zepbound Self Pay Journey Program. Eli Lilly also reduced the price of the <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">2.5 mg and 5 mg vials</a>.
These new offerings are available exclusively through LillyDirect Self-Pay Pharmacy Solutions, which enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43936046/lilly-launches-additional-zepbound-vial-doses-and-offers-new-savings-for-self-pay-patients" rel="noreferrer noopener">outside of insurance</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43600160/eli-lilly-seeks-to-expand-into-cancer-radiopharma-and-fatty-liver-with-two-global-deals" rel="noreferrer noopener">Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals</a>
Self-pay patients with obesity now have additional Zepbound vial options, including 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses. In addition to expanding the doses available, Lilly is taking steps to make Zepbound vials more affordable, including:
<ul>
<li>Lowering the price of the 2.5 mg dose to&nbsp;$349&nbsp;per month.</li>
<li>Lowering the price of the 5 mg dose to&nbsp;$499&nbsp;per month.</li>
<li>Launching the&nbsp;Zepbound Self Pay Journey Program, which reduces the price of the 7.5 mg&nbsp;($599)&nbsp;and 10 mg&nbsp;($699)&nbsp;doses to&nbsp;$499&nbsp;per month at first fill and refills that occur within 45 days of prior delivery.</li>
</ul>
Zepbound is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL doses in a single-dose pen (autoinjector).
The recommended maintenance dosages are 5 mg, 10 mg or 15 mg injected subcutaneously once weekly.
Those starting on Zepbound will take Zepbound 2.5 mg for four weeks before increasing their dosage to 5 mg.&nbsp;
Zepbound sales in the fourth quarter reached $1.91 billion, up from $175.8 million a year ago. Annual sales <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines" rel="noreferrer noopener">reached $4.93 billion</a>.
In August 2024, Eli Lilly released vials containing low doses of its weight-loss drug&nbsp;Zepbound (tirzepatide). Zepbound&nbsp;2.5 mg and 5 mg single-dose vials are&nbsp;available&nbsp;for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40573775/eli-lilly-releases-cheaper-zepbound-vials-priced-upto-50-lower-to-boost-access-supply-for-its-pop" rel="noreferrer noopener">response to high demand</a>.
Price Action: LLY stock is up 1.6% at $896 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43937535/home-depot-lifts-annual-dividend-after-strong-q4-but-soft-2025-outlook-weighs-on-stock" target="_blank" rel="noreferrer noopener">Home Depot Lifts Annual Dividend After Strong Q4, But Soft 2025 Outlook Weighs On Stock</a></li>
</ul>
Photo: Shutterstock

Eli Lilly Expands Zepbound Vial Options, Lowers Prices For 2.5 mg, 5 Mg Doses

Lilly To Acquire Organovo's FXR Program, Including FXR314; Terms Not Disclosed

Eli Lilly Launches 7.5 mg And 10 mg Zepbound Single-Dose Vials For $499 With The New Zepbound Self Pay Journey Program

VKTX

Drug Compounders Sue U.S. Drug Regulator Over Removal Of Novo Nordisk Diabetes, Weight Loss Drugs From Shortage List

Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly.
Looking at options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 53% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $328,270 and 10, calls, for a total amount of $923,536.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $760.0 to $1000.0 for Eli Lilly over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 415.89 with a total volume of 71.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $760.0 to $1000.0 over the last 30 days.
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740408351_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$99.65</td>
<td>$96.4</td>
<td>$99.55</td>
<td>$860.00</td>
<td>$696.8K</td>
<td align="right">850</td>
<td align="right">74</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$99.65</td>
<td>$96.9</td>
<td>$99.12</td>
<td>$860.00</td>
<td>$258.9K</td>
<td align="right">850</td>
<td align="right">38</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$6.35</td>
<td>$5.65</td>
<td>$6.0</td>
<td>$865.00</td>
<td>$240.0K</td>
<td align="right">438</td>
<td align="right">0</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$99.2</td>
<td>$96.6</td>
<td>$99.2</td>
<td>$860.00</td>
<td>$138.8K</td>
<td align="right">850</td>
<td align="right">38</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$98.7</td>
<td>$96.5</td>
<td>$98.7</td>
<td>$860.00</td>
<td>$128.3K</td>
<td align="right">850</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>Currently trading with a volume of 16,241, the LLY's price is up by 0.27%, now at $876.01. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 66 days.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $1066.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Eli Lilly with a target price of $1038. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1190. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Eli Lilly, maintaining a target price of $970. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Eli Lilly's Options: A Look at What the Big Money is Thinking

President Donald Trump reportedly issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the U.S. or face the possibility of tariffs.
What Happened: During a confidential meeting, Trump alerted drug companies about the impending tariffs, urging them to hasten the transfer of their overseas production to the U.S., reported <a href="https://www.bloomberg.com/news/articles/2025-02-21/trump-told-drugmakers-to-move-production-to-us-or-face-tariffs">Bloomberg</a> on Friday.
On Thursday, the CEO of Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) David Ricks, CEO of Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Robert Davis, CEO OF Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Albert Bourla, and Stephen Ubl, head of the industry&#8217;s largest lobbying group met Trump at the White House. The executives aimed to persuade Trump to back efforts to limit a law permitting the federal government to negotiate specific drug prices and to support measures targeting middlemen whom the industry holds responsible for increasing out-of-pocket costs.
As per the Bloomberg report, Trump did not assure to advocate with Congress to alleviate a drug pricing program established under former President Joe Biden&#8216;s tenure, a relief that the pharmaceutical sector has been seeking.
Medicare officials confirmed on Friday that the next phase of the drug pricing negotiation program&nbsp;is due and would include Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) blockbuster weight loss drugs, Ozempic and Wegovy. 
Meanwhile, Trump stated that Health and Human Services Secretary Robert F. Kennedy Jr. and his nominee for leading Medicare and Medicaid, Mehmet Oz, are working to reduce drug prices.
SEE ALSO: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43904842/dominos-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Domino&#8217;s Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Why It Matters: Last week, Trump proposed to <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">impose a 25% tariff </a>on pharmaceuticals imported to the U.S. This latest move by Trump is not surprising given his previous confrontations with the pharmaceutical industry. During his first term, he even accused them at one point of &#8220;getting away with murder&#8221; with their drug pricing. 
ING Bank estimates that the U.S. imported nearly 36% of the drugs in 2024 with Ireland, Germany, and Switzerland being the top importers. Meanwhile, data from the Atlantic Council shows that U.S. imports of Chinese drugs surged 485% between 2020-2022.&nbsp;Following Trump&#8217;s latest warning to drugmakers to shift production in the U.S., Chinese biotech shares have taken a hit during their Asian trading session today. Shares of WuXi Biologics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WXXWY#OTC">WXXWY</a>), WuXi AppTec (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WUXAY#OTC">WUXAY</a>) and Pharmaron Beijing (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PHBBF#OTC">PHBBF</a>) witnessed significant declines. 
That being said, ING asserted that Trump&#8217;s call for expanding U.S. pharmaceutical manufacturing is justified, as a report from the Biden administration had indicated that capacity restrictions were the cause of drug shortages. However, a 2022 report by Washington University&nbsp;revealed that the capacity expansion would take between two to three years. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/02/43901182/bernie-sanders-warns-if-elon-musk-can-fire-hundreds-of-thousands-of-federal-employees-imagine-what-hell-do-to-private-sector-workers">Bernie Sanders Warns: If Elon Musk Can Fire Hundreds Of Thousands Of Federal Employees, Imagine What He&#8217;ll Do To Private Sector Workers</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

PHBBF

WUXAY

WXXWY

Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs

DRIO

LFVN

RHHBY

TERN

VANI

FDA Says Novo Nordisk's Ozempic Injection .68 mg/1 ml, Injection 1.34 mg/1 ml, Injection 2.68 Mg/1 ml Available As Of Feb 21; Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml , Wegovy, Injection, 2.4 mg/.75 ml Now Available; FDA Says Semaglutide Injection Shortage Is Resolved As Of Feb 21

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 46 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 39%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $378,149, and 38 are calls, for a total amount of $5,040,761.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $750.0 and $1080.0 for Eli Lilly, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $750.0 to $1080.0 in the last 30 days. 
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740079838_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$70.15</td>
<td>$67.5</td>
<td>$69.0</td>
<td>$1000.00</td>
<td>$2.7M</td>
<td align="right">300</td>
<td align="right">1</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$70.0</td>
<td>$65.9</td>
<td>$69.0</td>
<td>$1000.00</td>
<td>$690.0K</td>
<td align="right">300</td>
<td align="right">401</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$135.8</td>
<td>$134.3</td>
<td>$135.8</td>
<td>$840.00</td>
<td>$162.9K</td>
<td align="right">142</td>
<td align="right">0</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$12.0</td>
<td>$11.75</td>
<td>$12.0</td>
<td>$870.00</td>
<td>$97.2K</td>
<td align="right">98</td>
<td align="right">183</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$37.7</td>
<td>$36.85</td>
<td>$37.7</td>
<td>$880.00</td>
<td>$79.1K</td>
<td align="right">208</td>
<td align="right">28</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Eli Lilly</h3>
<ul>
<li>With a volume of 1,600,917, the price of LLY is up 0.69% at $873.03. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 70 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1066.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $970. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Eli Lilly, targeting a price of $1038. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Eli Lilly with a target price of $1190. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Raw Materials and Product Supply
Most of the principal materials we use in our manufacturing operations are available from more than one source. However, certain materials are procured from a single source. We seek to maintain sufficient inventory to provide reliability of production and manage unforeseen supply variability. However, various developments have led, and may in the future lead, to interruption or shortages in supply until we establish new sources, implement alternative processes, bring new manufacturing facilities online, or pause or discontinue product sales in one or more markets.
Our active ingredient manufacturing and finishing operations, including formulation, filling, assembling, delivery device manufacturing, and packaging, take place at sites in the U.S., including Puerto Rico, Ireland and a number of other sites throughout the world. To support anticipated demand for our current and prospective products, we have undertaken significant manufacturing expansion initiatives. Investments to increase our manufacturing capacity include sites in North Carolina, Wisconsin, Ireland, Germany, and two in Indiana. We also utilize and are expanding arrangements with third parties for certain active ingredient manufacturing, filling, finishing operations, and for device or component production and assembly. Among these third parties, we, and the pharmaceutical industry generally, depend on China-based suppliers for portions of our supply chain. U.S. federal lawmakers are considering legislation that is intended to limit supply chain reliance on China, including the proposed BIOSECURE Act. In addition, historically, geopolitical tensions between the U.S. and China have led to the imposition of tariffs, sanctions, and certain other business restrictions between the U.S. and China. In February 2025, the U.S. presidential administration imposed new tariffs on China and China responded with tariffs on select U.S. goods. If new legislation or additional trade restrictions are adopted or geopolitical tensions were to increase and disrupt our operations in, or related to, China, such disruption could significantly impact our business and results of operations. See Item 1A, "Risk Factors—Risks Related to Our Operations—Reliance on third-party relationships and outsourcing arrangements could adversely affect our business" and "Risk Factors—Risks Related to Doing Business Internationally—Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results," for additional information.
We manage our supply chain (including our own facilities, contracted arrangements, and inventory) in a way that is intended to allow us to meet product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to changes in supply and demand. To maintain supply of our products, we use a variety of techniques, including comprehensive quality systems, inventory management, and back-up sites.
However, pharmaceutical production processes are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity is a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, developments such as unanticipated demand, unplanned plant shutdowns, manufacturing or quality assurance difficulties at one of our facilities or contracted facilities, failure or refusal of a supplier or contract manufacturer to supply contracted quantities in a timely manner or at all, increases in demand on a supplier, or difficulties in predicting or variability in demand for and supply of our products and those of our competitors have led, and may in the future lead, to interruption or higher costs in the supply of certain products, product shortages, or pauses or discontinuations of product sales in one or more markets. For example, in periods of 2024, demand for our incretin medicines exceeded production. Supply and channel dynamics in some cases also contribute to variability in financial results for our products from period to period. Further, cost and wage inflation, availability of adequate capacity in global transportation, supply chain complexities, including consolidation therein, labor market issues, international tension and conflicts, uneven economic growth or downturns, an increase in overall demand in our industry for certain products and materials, and public health outbreaks, epidemics, or pandemics, have caused, and in the future may cause, delays or disruptions in and/or increased costs related to distribution of our medicines, the construction or acquisition of manufacturing capacity, procurement activity, and supplier or contract manufacturer arrangements, as well as other general business impacts. For more information on the additional risks we face in connection with any difficulties, disruptions, and shortages in the manufacturing, distribution, and sale of our products, see Item 1A, "Risk Factors—Risks Related to Our Business—Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems."

Global

Eli Lilly Says If U.S. Governments New Trade Restrictions On China Are Adopted, It Could Impact Our Business And Results Of Operations

On Friday, the FDA approved Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Merilog as a biosimilar to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Novolog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes mellitus.
Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43692253/sanofi-johnson-johnson-partnered-vaccine-against-bacterial-sepsis-flunks-late-stage-study" rel="noreferrer noopener">Sanofi/Johnson &amp; Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study</a>
As a rapid-acting insulin, Merilog helps lower mealtime blood sugar spikes and improve blood sugar control in people with diabetes. The <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes" rel="noreferrer noopener">approval </a>is for a 3 milliliter (mL) single-patient-use prefilled pen and a 10 milliliter (mL) multiple-dose vial.
Merilog is the third insulin biosimilar product the FDA has approved, joining the two long-acting insulin biosimilar products the agency approved in 2021.
A biosimilar is a &#8220;biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA (also called the reference product).&#8221; The FDA has approved 65 biosimilar products to date.
Like Novolog, Merilog should be administered within five to ten minutes before the start of a meal. Merilog is administered subcutaneously (under the skin) by injection into the stomach, buttocks, thighs, or upper arms. Dosing of Merilog should be individualized and adjusted based on the patient&#8217;s needs.
Merilog may cause serious side effects, including hypoglycemia (low blood sugar), severe allergic reactions, and hypokalemia (low potassium in blood). Other common side effects may include injection site reactions, itching, rash, lipodystrophy (skin thickening or pitting at the injection site), weight gain, and swelling of hands and feet.
In 2023, Sanofi jumped the bandwagon with the other two insulin U.S. giants to&nbsp;lower the price of its best-selling insulin product, Lantus <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31394427/three-is-company-sanofi-follows-lilly-novo-nordisk-slashes-insulin-product-price-by-78" rel="noreferrer noopener">(insulin glargine), by 78%</a>.
Sanofi said it would cap a&nbsp;Lantus patient&#8217;s monthly out-of-pocket cost at $35 for all patients with commercial insurance.&nbsp;
Also, in 2023, Sanofi acquired&nbsp;Provention Bio for $25.00 per share in cash, representing an equity value of <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31318877/provention-bios-2-9b-acquisition-a-strategic-fit-for-sanofi" rel="noreferrer noopener">approximately $2.9 billion</a>.
The transaction adds a type 1 diabetes therapy to Sanofi&#8217;s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.&nbsp;
In November, Doctors Without Borders/Médecins Sans Frontières highlighted that&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk, and Sanofi, which dominate the global insulin market, have the power to set high&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price" rel="noreferrer noopener">prices that restrict access</a>.
According to MSF, data published in&nbsp;JAMA Network Open&nbsp;shows that insulin pens could be produced for as little as $0.94 per unit and remain profitable, yet current prices far exceed this figure.
Price Action: SNY stock is down 0.59% at $54.18 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43744606/analyst-cautiously-optimistic-on-dexcom-as-competitive-pressures-loom" target="_blank" rel="noreferrer noopener">Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom</a></li>
</ul>
Image by HJBC via Shutterstock

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes

Billionaire investor Stanley Druckenmiller&#8216;s family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent 13-F filing.
What Happened: According to a recent&nbsp;SEC filing, Druckenmiller, a seasoned investor, sold all his shares of&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) in the fourth quarter. This move comes on the heels of his total exit from Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), a competing chipmaker, a few months prior.
In the closing months of 2024, Druckenmiller significantly reduced his tech stock portfolio, selling his entire stakes in&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>),&nbsp;Adobe Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) and&nbsp;Autodesk Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>). He also completely sold his stake in&nbsp;Starbucks Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) and his shares in insurance company&nbsp;Chubb Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>).
Despite these divestments, Druckenmiller increased his investments in several big tech companies in the same quarter, acquiring new positions in&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>),&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Elon Musk&#8216;s electric vehicle manufacturer&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Druckenmiller&#8217;s Duquesne also initiated new investments in United Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NYSE">UAL</a>), Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), Warner Bros. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>), Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), and Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
The most significant holding in his Duquesne Family Office remains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), the clinical genetic-testing company in which they held a stake since 2022. Natera holdings account for just over 15% of the portfolio. Meanwhile, the firm increased its stake in Teva Pharmaceuticals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) by nearly 6.3 times. 
SEE ALSO: <a href="https://www.benzinga.com/25/02/43649046/warner-bros-jinjiang-international-collaborate-for-harry-potter-studio-tour-in-shanghai">Warner Bros Announces Shanghai Harry Potter Studio Tour—Set To Be Four Times Larger Than London&#8217;s</a>
Why It Matters: Druckenmiller, who formerly managed hedge funds for George Soros, now manages his own wealth through the Duquesne Family Office, which has investments worth nearly $3.72 billion.
The billionaire investor&#8217;s latest moves follow his earlier divestments in AI stocks. During the third quarter of 2024, <a href="https://www.benzinga.com/markets/equities/24/12/42668157/stanley-druckenmiller-dumps-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-betting-on-next">Druckenmiller sold all of its Nvidia shares and significantly reduced its Palantir holdings</a> by 95%. This occurred despite Nvidia and Palantir experiencing significant stock surges that year, with Nvidia&#8217;s stock increasing nearly 190% and Palantir&#8217;s shares gaining over 386%. 
The current quarter&#8217;s exit from Broadcom despite the stock surging more than 100% over the past year appears as a profit booking move. Meanwhile, other additions in big tech stocks show his growing confidence in the sector.
Druckenmiller added Tesla to its portfolio which surged over 83% in the past year. However, the stock plunged more than 16% over the last month, amid declining global sales, regulatory roadblocks in China, earnings disappointment, and Musk&#8217;s increasing political involvement. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">Tesla&#8217;s Refreshed Model Y Rolls Off Shanghai Gigafactory, Deliveries To Start &#8216;Soon&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4

Press Releases

Lilly reports full Q4 2024 financial results and provides 2025 guidance

Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

Lilly to participate in TD Cowen's 45th Annual Health Care Conference

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

Contracts

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Lilly to participate in Leerink Partners Global Healthcare Conference

Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA

ENVB

PNPNF

PRSO

TRNR

TSXV:PNPN

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Truist Securities

Wells Fargo

Citigroup

B of A Securities

Wolfe Research

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Comments

Eli Lilly

Noticias

Últimas noticias sobre Eli Lilly (NYSE:LLY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL